medigraphic.com
ISSN 1527-3172 (Digital)

2021, Número 2

<< Anterior Siguiente >>

MEDICC Review 2021; 23 (2)


Implications of Low-grade Inflammation in SARS-CoV-2 Immunopathology

Suárez-Reyes A, Villegas-Valverde CA

Idioma: Ingles.
Referencias bibliográficas: 124
Paginas: 42-54
Archivo PDF: 523.12 Kb.


RESUMEN

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Sun J, He W-T, Wang L, Lai A, Ji X, Zhai X, et al.COVID-19: epidemiology, evolution, and crossdisciplinaryperspectives. Trends Mol Med. 2020May 1;26(5):483–95.

  2. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, etal. Clinical features of patients infected with 2019novel coronavirus in Wuhan, China. Lancet. 2020Feb 15;395(10223):497–506.

  3. Han Q, Lin Q, Jin S, You L. Coronavirus 2019-nCoV: a brief perspective from the front line. JInfect. 2020 Apr 1;80(4):373–7.

  4. Fuk-Woo CJ, Kok K, Zhu Z, Chu H, Kai-WangTK, Yuan S, et al. Genomic characterization ofthe 2019 novel human pathogenic coronavirusisolated from a patient with atypical pneumoniaafter visiting Wuhan. Emerg Microbes Infect.2020 Jan 28;9(1):221–36.

  5. Shereen MA, Khan S, Kazmi A, Bashir N, SiddiqueR. COVID-19 infection: origin, transmission,and characteristics of human coronaviruses.J Adv Res. 2020 Mar 16;24:91–8.

  6. Wu D, Wu T, Liu Q, Yang Z. The SARS-CoV-2outbreak: what we know. Int J Infect Dis. 2020May;94:44–8.

  7. Hoque MN, Chaudhury A, Akanda MdAM, HossainMA, Islam Md Tofazzal. Genomic diversityand evolution, diagnosis, prevention, and therapeuticsof the pandemic COVID-19 disease. PeerJ. 2020 Sep 1;8:e9689. DOI: 10.7717/peerj.9689

  8. Ovsyannikova IG, Haralambieva IH, Crooke SN,Poland GA, Kennedy RB. The role of host geneticsin the immune response to SARSCoV-2 andCOVID-19 susceptibility and severity. ImmunolRev. 2020 Jul;296(1):205–19.

  9. Gill SE, Dos Santos CC, O’Gorman DB, CarterDE, Patterson EK, Slessarev M, et al. Transcriptionalprofi ling of leukocytes in critically illCOVID19 patients: implications for interferonresponse and coagulation. Intensive Care MedExp. 2020 Dec 11;8:75. DOI: 10.1186/s40635-020-00361-9

  10. McCoy K, Peterson A, Tian Y, Sang Y. Immunogeneticassociation underlying severeCOVID-19. Vaccines (Basel). 2020 Nov20;8(4):700.

  11. Di Maria E, Latini A, Borgiani P, Novelli G.Genetic variants of the human host infl uencingthe coronavirus-associated phenotypes (SARS,MERS and COVID-19): rapid systematic reviewand fi eld synopsis. Hum Genomics. 2020 Sep11;14(1):30.

  12. Kenney AD, Dowdle JA, Bozzacov L, McMichaelTM, Gelais CS, Panfi l AR, et al. Human geneticdeterminants of viral diseases. Annu Rev Genet.2017 Nov 27;51:241–63.

  13. Wang X, Fang X, Cai Z, Wu X, Gao X, MinJ, et al. Comorbid chronic diseases and acuteorgan injuries are strongly correlated with diseaseseverity and mortality among COVID-19patients: a systemic review and meta-analysis.Research (Wash DC). 2020;2402961. DOI:10.34133/2020/2402961

  14. Liu H, Chen Sh, Liu M, Nie H, Lu H. Comorbidchronic diseases are strongly correlated withdisease severity among COVID-19 patients: asystematic review and meta-analysis. Aging Dis.2020 May 9;11(3):668–78.

  15. Fu L, Wang B, Yuan T, Chen X, Ao Y, FitzpatricT, et al. Clinical characteristics of coronavirusdisease 2019 (COVID-19) in China: a systematicreview and meta-analysis. J Infec. 2020Jun;80(6):656–65.

  16. Rodríguez-Morales AJ, Cardona-Ospina JA,Gutiérrez-Ocampo E, Villamizar-Peña R, Holguín-Rivera Y, Escalera-Antezana JP, et al.Clinical, laboratory and imaging features ofCOVID-19: a systematic review and metaanalysis.Travel Med Infect Dis. 2020 Mar–Apr;34:101623. DOI: 10.1016/j.tmaid.2020.101623

  17. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, etal. Clinical characteristics of 138 hospitalizedpatients with 2019 Novel Coronavirus-infectedpneumonia in Wuhan, China. JAMA. 2020 Mar17;323(11):1061–9.

  18. Jain V, Yuan JM. Predictive symptoms andcomorbidities for severe COVID-19 and intensivecare unit admission: a systematic reviewand meta-analysis. Int J Public Health. 2020Jun;65(5):533–46.

  19. Kang SJ, Jung SI. Age-related morbidity andmortality among patients with COVID-19. InfectChemother. 2020 Jun;52(2):154–64.

  20. Shahid Z, Kalayanamitra R, McClafferty B,Kepko D, Ramgobin D, Patel R, et al. COVID-19and older adults: what we know. J Am GeriatrSoc. 2020 May;68(5):926–9.

  21. Tay MZ, Poh CM, Rénia L, MacAry PA, NgLFP. The trinity of COVID-19: immunity, infl ammationand intervention. Nat Rev Immunol. 2020Jun;20(6):363–74.

  22. Comunicado de Prensa. Creciendo a un ritmomenor, se espera que la población mundialalcanzará 9.700 millones en 2050 y unmáximo de casi 11.000 millones alrededor de2100: Informe de la ONU [Internet]. New York:United Nations, Department of Public Information;2019 [cited 2020 Dec 24]. 4 p. Available at:https://population.un.org/wpp/Publications/Files/WPP2019_PressRelease_ES.pdf. Spanish.

  23. World Health Organization [Internet]. Geneva:World Health Organization; c2021. Newsroom.Fact sheets. Enfermedades no transmisibles;[updated 2018 Jun 1; cited 2020 Dec 24]. Availableat: https://www.who.int/es/news-room/fact-sheets/detail/noncommunicable-diseases.Spanish.

  24. National Health Statistics and Medical RecordsDivision (CU). Anuario Estadístico de Salud2019 [Internet]. Havana: Ministry of Public Health(CU); 2020 [cited 2020 Dec 24]. 206 p. Availableat: http://www.sld.cu/anuncio/2020/05/09/publicado-el-anuario-estadistico-de-salud-2019.Spanish.

  25. Horton R. Offl ine: COVID-19 is not a pandemic.Lancet. 2020 Sep 26;396(10255):874.

  26. Prete M, Favoino E, Catacchio G, Racanelli V,Perosa F. SARS-CoV-2 Infl ammatory Syndrome.Clinical features and rationale for immunologicaltreatment. Int J Mol Sci. 2020 May 10;21(9):3377.

  27. Abbas AK, Litchman AH, Pillai S. Inmunologíacelular y molecular. 8va. ed. Barcelona: ElsevierEspaña; 2015. Chapter 1, Propiedades y generalidadesde las respuestas inmunitarias; p. 1–12.Spanish.

  28. Fulop T, Larbi A, Dupuis G, Le Page A, FrostEH, Cohen AA, et al. Immunosenescenceand infl amm-aging as two sides of the samecoin: friends or foes? Front Immunol. 2018 Jan10;8:1960. DOI: 10.3389/fi mmu.2017.01960

  29. Vabret N, Britton GJ, Gruber C, Hegde S, KimJ, Kuksin M, et al. Immunology of COVID-19:current state of the science. Immunity. 2020 Jun16;52(6):910–41.

  30. Jonsdottir HR, Dijkman R. Coronaviruses and thehuman airway: a universal system for virus-hostinteraction studies. Virol J. 2016 Feb 6;13:24.DOI: 10.1186/s12985-016-0479-5

  31. Nikolich-Zugich J, Knox KS, Tafi ch Rios C, NattB, Bhattacharya D, Fain MJ. SARS-CoV-2 andCOVID-19 in older adults: what we may expectregarding pathogenesis, immune responses, andoutcomes. GeroScience. 2020 Apr;42(2):505–14.

  32. Jafarzadeh A, Chauhan P, Saha B, Jafarzadeh S,Nemati M. Contribution of monocytes and macrophagesto the local tissue infl ammation and cytokinestorm in COVID-19: Lessons from SARSand MERS, and potential therapeutic interventions.Life Sci. 2020 Sep 15;257:118102. DOI:10.1016/j.lfs.2020.118102

  33. Rohit G, Abdou Y, Singh A, Rana N, Puzanov I,Ernstoff MS. COVID-19 and cancer: a comprehensivereview. Curr Oncol Rep. 2020 May8;22(5):53. DOI: 10.1007/s11912-020-00934-7

  34. Zhang D, Guo R, Lei L, Liu H, Wang Y, Wang Y,et al. COVID-19 infection induces readily detectablemorphologic and infl ammation-related phenotypicchanges in peripheral blood monocytes.J Leukoc Biol. 2021 Jan;109(1):13–22.

  35. Pence BD. Severe COVID-19 and aging:are monocytes the key? GeroScience. 2020Aug;42(4):1051–61.

  36. Bektas A, Schurman SH, Franceschi C, FerrucciL. A public health perspective of aging: do hyperinflammatory syndromes such as COVID-19,SARS, ARDS, cytokine storm syndrome, andpost-ICU syndrome accelerate short- and longterminfl ammaging? Immun Ageing. 2020 Aug24;17:23 DOI: 10.1186/s12979-020-00196-8

  37. Figueira Gonçalves JM, Golpe R. Clinical challengesin chronic obstructive pulmonary diseasein patients who suffered SARS-CoV-2 infection.Med Clin (Barc). 2020 Aug 28;155(4):162–4.English, Spanish.

  38. Sardu C, Gambardella J, Morelli MB, Wang X,Marfella R, Santulli G. Hypertension, thrombosis,kidney failure, and diabetes: is COVID-19 anendothelial disease? A comprehensive evaluationof clinical and basic evidence. J Clin Med.2020 May;9(5):1417. DOI: 10.3390/jcm9051417

  39. Matsushita K, Marchandot B, Jesel L, OhlmannP, Morel O. Impact of COVID-19 on the cardiovascularsystem: a review. J Clin Med. 2020May;9(5):1407. DOI:10.3390/jcm9051407

  40. Mattioli AV, Puviani MB, Nasi M, Farinetti A.COVID-19 pandemic: the effects of quarantineon cardiovascular risk. Eur J Clin Nutr. 2020Jun;74(6):852–5.

  41. Mathew D, Giles JR, Baxter AE, Oldridge DA,Greenplate AR, Wu JE, et al. Deep immune profiling of COVID-19 patients reveals distinct immunotypeswith therapeutic implications. Science.2020 Sep 4;369(6508):eabc8511. DOI: 10.1126/science.abc8511

  42. Guzik TJ, Mohiddin SA, Dimarco A, Patel V, SavvatisK, Marelli-Berg FM, et al. COVID-19 andthe cardiovascular system: implications for riskassessment, diagnosis, and treatment options.Cardiovasc Res. 2020 Aug 1;116(10):1666–87.

  43. Addeo A, Friedlaender A. Cancer and COVID-19:unmasking their ties. Cancer Treat Rev. 2020Aug;88:102041. DOI: 10.1016/j.ctrv.2020.102041

  44. Krabbe KS, Pedersen M, Bruunsgaard H. Infl ammatorymediators in the elderly. Exp Gerontol.2004 May;39(5):687–99.

  45. Medzhitov R. Origin and physiologicalroles of infl ammation. Nature. 2008 Jul24;454(7203):428–35.

  46. Chung HY, Kim DH, Lee EK, Chung KW, ChungS, Lee B, et al. Redefi ning chronic infl ammationin aging and age-related diseases: proposal ofthe senoinfl ammation concept. Aging Dis. 2019Apr 1;10(2):367–82.

  47. Hawiger J, Zienkiewicz J. Decoding infl ammation,its causes, genomic responses, and emergingcountermeasures. Scand J Immunol. 2019Dec;90(6):e12812. DOI: 10.1111/sji.12812

  48. Ferrucci L, Fabbri E. Infl ammageing: chronic infl ammationin ageing, cardiovascular disease, and frailty.Nat Rev Cardiol. 2018 Sep;15(9):505–22.

  49. Rock KL, Latz E, Ontiveros F, Kono H. The sterileinfl ammatory response. Annu Rev Immunol.2010;28:321–42. DOI: 10.1146/annurev-immunol-030409-101311.

  50. Bektas A, Schurman SH, Sen R, FerrucciL. Human T cell immunosenescence andinfl ammation in aging. J Leukoc Biol. 2017Oct;102(4):977–88.

  51. Martínez–Aguilar NE, Vargas–Camaño ME,Hernández–Pliego RR, Chaia–Semerena GM,Pérez–Chavira MR. Inmunopatología de laenfermedad pulmonar obstructiva crónica. RevAlerg Mex. 2017;64(3):327–46. Spanish.

  52. Crouch EC, Hirche TO, Shao B, Boxio R, WartelleJ, Benabid R, et al. Myeloperoxidasedependentinactivation of surfactant proteinD in vitro and in vivo. J Biol Chem. 2010 May28;285(22):16757–70.

  53. Flaherty GT, Hession P, Liew CH, Wei LimBC, Leong TK, Lim V, et al. COVID-19 in adultpatients with preexisting chronic cardiac, respiratoryand metabolic disease: a critical literaturereview with clinical recommendations. TropDis Travel Med Vaccines. 2020 Aug 28;6:16DOI:10.1186/s40794-020-00118-y

  54. Zhang J, Wang X, Jia X, Li J, Hu K, Chen G,et al. Risk factors for disease severity, unimprovement,and mortality in COVID-19 patientsin Wuhan, China. Clin Microbiol Infect. 2020Jun;26(6):767–72.

  55. Richardson S, Hirsch JS, Narasimhan M,Crawford JM, McGinn T, Davidson KW, et al.Presenting characteristics, comorbidities, andoutcomes among 5700 patients hospitalized withCOVID-19 in the New York City area. JAMA.2020 May 26;323(20):2052–9.

  56. Kowald A, Passos JF, Kirkwood TBL. On the evolutionof cellular senescence. Aging Cell. 2020Dec;19(12):e13270. DOI: 10.1111 / acel.13270

  57. Hamsanathan S, Alder JK, Sellares J, RojasM, Gurkar AU, Mora AL. Cellular senescence:the Trojan horse in chronic lung diseases. Am JRespir Cell Mol Biol. 2019 Jul;61(1):21–30.

  58. Nikolich-Zugich J. Ageing and life-long maintenanceof T-cell subsets in the face of latentpersistent infections. Nat Rev Immunol. 2008Jul;8(7):512–22.

  59. Suárez GM, Saavedra D. Manipulación de lainmunosenescencia. Rev Cubana HematolInmunol Hemoter [Internet]. 2018 Jan–Mar [cited2020 Dec 24];34(1):33–41. Available at: http://www.revhematologia.sld.cu/index.php/hih/article/view/584/767. Spanish.

  60. Thomas R, Wang W, Su DM. Contributionsof age-related thymicinvolution to immunosenescence and infl ammaging.Immun Ageing. 2020 Jan 20;17:2.DOI: 10.1186/s12979-020-0173-8

  61. Franceschi C, Monti D, Barbieri D, Salvioli S,Grassilli E, Capri M, et al. Successful immunosenescenceand the remodeling of immuneresponses with ageing. Nephrol Dial Transplant.1996;11 Suppl 9:18–25.

  62. Motta M, Ferlito L, Malaguarnera L, Vinci E, BoscoS, Maugeri D, et al. Alterations of the lymphocyticset-up in elderly patients with cancer. ArchGerontol Geriatr. 2003 Jan–Feb;36(1):7–14.

  63. García B, Lage A. Inmunosenescencia: implicacionespara la inmunoterapia de cáncer en los adultosmayores. Biotecnol Apl [Internet]. 2006 [cited2020 Dec 24];23:186–93. Available at: https://bibla t.unam.mx/es/revista/biotecnologia-aplicada/articulo/inmunosenescencia-implicaciones-para-la-inmunoterapia-de-cancer-en-los-adultos-mayores. Spanish.

  64. Fülöp T, Dupuis G, Witkowski JM, Larbi A. Therole of immunosenescence in the developmentof age-related diseases. Rev Inves Clin. 2016Mar–Apr;68(2):84–91.

  65. Agrawal A, Gupta S. Impact of aging on dendriticcell functions in humans. Ageing Res Rev. 2011Jul;10(3):336–45.

  66. Cunha LL, Perazzio SF, Azzi J, Cravedi P, RiellaLV. Remodeling of the immune response withaging: immunosenescence and its potentialimpact on COVID-19 immune response. FrontImmunol. 2020 Aug 7;11:1748. DOI: 10.3389/fi mmu.2020.01748

  67. Grubeck-Loebenstein B, Wick G. The aging of theimmune system. Adv Immunol. 2002;80:243–84.

  68. Pawelec G. Age and immunity: what is “immunosenescence”?Exp Gerontol. 2018 May;105:4–9.

  69. Yang JK, Lin SS, Ji XJ, Guo LM. Binding ofSARS coronavirus to its receptor damages isletsand causes acute diabetes. Acta Diabetol. 2010Sep;47(3):193–9.

  70. van Baarle D, Tsegaye A, Miedema F, Akbar A.Signifi cance of senescence for virus-specifi cmemory T cell responses: rapid ageing duringchronic stimulation of the immune system. ImmunolLett. 2005 Feb 15;97(1):19–29.

  71. Franceschi C, Monti D, Sansoni P, Cossarizza A.The immunology of exceptional individuals: thelesson of centenarians. Immunol Today. 1995Jan;16(1):12–6.

  72. Wang B, Li R, Lu Z, Huang Y. Does comorbidityincrease the risk of patients with COVID-19:evidence from meta-analysis. Aging (Albany NY).2020 Apr 8;12(7):6049–57.

  73. Ekiz T, Pazarl AC. Relationship between COVID-19 and obesity. Diabetes Metab Syndr. 2020Sep–Oct;14(5):761–3.

  74. Muscogiuri G, Pugliese G, Barrea L, SavastanoS, Colao A. Comentary: Obesity: The“Achilles heel” for COVID-19? Metabolism.2020 Jul 1;108:154251. DOI:10.1016/j.metabol.2020.154251

  75. Kumar A, Arora A, Sharma P, Anikhindi SA,Bansal N, Singla V, et al. Is diabetes mellitusassociated with mortality and severity ofCOVID-19? A meta-analysis. Diabetol MetabSyndr. 2020 Jul–Aug;14(4):535–45.

  76. Hu Y, Sun J, Dai Z, Deng H, Li X, Huang Q, et al.Prevalence and severity of corona virus disease2019 (COVID-19): a systematic review and metaanalysis.J Clin Virol. 2020 Jun;127:104371. DOI:10.1016/j.jcv.2020.104371

  77. ElGohary GM, Hashmi S, Styczynski J, Kharfan-Dabaja MA, Alblooshi RM, de la Cámara R, etal. The risk and prognosis of COVID-19 infectionin cancer patients: a systematic review andmeta-analysis. Hematol Oncol Stem Cell Ther[Internet]. 2020 Jul 30 [cited 2020 Dec 24]. DOI:10.1016/j.hemonc.2020.07.005. Online ahead ofprint. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7390725/

  78. Liang W, Guan W, Chen R, Wang W, Li J, Xu K,et al. Comment: Cancer patients in SARS-CoV-2infection: a nationwide analysis in China. LancetOncol. 2020 Mar;21(3):335–7.

  79. Barbé-Tuana F, Funchal G, Schmitz CRR, MaurmannRM, Bauer ME. The interplay betweenimmunosenescence and age-related diseases.Semin Immunopathol. 2020 Oct;42(5):545–57.

  80. Chait A, den Hartigh LJ. Adipose tissue distribution,inflammation and its metabolicconsequences, including diabetes and cardiovasculardisease. Front Cardiovasc Med. 2020Feb 25;7:22. DOI: 10.3389/fcvm.2020.00022

  81. Burhans MS, Hagman DK, Kuzma JN, SchmidtKA, Kratz M. Contribution of adipose tissueinfl ammation to the development of type 2 diabetesmellitus. Compr Physiol. 2018 Dec 13;9(1):1–58.

  82. Petrakis D, Margină D, Tsarouhas K, Tekos F,Stan M, Nikitovic D, et al. Obesity - a risk factorfor increased COVID-19 prevalence, severityand lethality. Mol Med Rep. 2020 Jul;22(1):9–19.

  83. Boutens L, Stienstra R. Adipose tissue macrophages:going off track during obesity. Diabetologia.2016 May;59(5):879–94.

  84. Geng S, Chen K, Yuan R, Peng L, Maitra U,Diao N, et al. The persistence of low-gradeinflammatory monocytes contributes to aggravatedaterosclerosis. Nat Commun. 2016 Nov8;7:13436. DOI: 10.1038/ncomms13436

  85. Laird E, Rhodes J, Kenny RA. Vitamin D andinfl ammation: potential implications for severityof COVID-19. Ir Med J. 2020 May 7;113(5):81.

  86. Li MY, Li L, Zhang Y, Wang XS. Expression ofthe SARS-CoV-2 cell receptor gene ACE2 in awide variety of human tissues. Infect Dis Poverty.2020 Apr 28;9(1):45. DOI: 10.1186/s40249-020-00662-x

  87. Al-Benna S. Association of high level geneexpression of ACE2 in adipose tissue with mortalityof COVID-19 infection in obese patients.Obes Med. 2020 Sep;19:100283. DOI: 10.1016/j.obmed.2020.100283

  88. Serra Valdés MA. Las enfermedades crónicasno transmisibles y la pandemia por COVID-19.Rev Finlay [Internet]. 2020 Jun [cited 2020 Dec25];10(2):78–88. Available at: http://www.revfinlay.sld.cu/index.php/finlay/article/view/846.Spanish.

  89. Williams B, Mancia G, Spiering W, RoseiEA, Azizi M, Burnier M, et al. 2018 ESC/ESHGuidelines for the management of arterial hypertension:The Task Force for the management ofarterial hypertension of the European Societyof Cardiology (ESC) and the European Societyof Hypertension (ESH). Eur Heart J. 2018 Sep1;39(33):3021–104.

  90. Wenzel U, Turner JE, Krebs C, Kurts C, HarrisonDG, Ehmke H. Immune mechanisms in arterialhypertension. J Am Soc Nephrol. 2016 Mar;27(3):677–86.

  91. Norlander AE, Madhur MS, Harrison DG. Theimmunology of hypertension. J Exp Med. 2018Jan 2;215(1):21–33.

  92. Siedlinski M, Jozefczuk E, Xu X, Teumer A, EvangelouE, Schnabel RB, et al. White blood cellsand blood pressure. A Mendelian randomizationstudy. Circulation. 2020 Apr 21;141(16):1307–17.

  93. Rodríguez-Iturbe B. The participation of immunityin the pathogenesis of arterial hypertension.Nefrologia. 2020 Jan–Feb;40(1):1–3. English,Spanish.

  94. Youn JC, Yu HT, Lim BJ, Koh MJ, Lee J, ChangDY, et al. Immunosenescent CD8+ T Cells andC-X-C chemokine receptor type 3 chemokinesare increased in human hypertension. Hypertension.2013 Jul;62(1):126–33.

  95. Virchow R. Cellular pathology. As based uponphysiological and pathological histology. LectureXVI--Atheromatous affection of arteries. 1858.Nutr Rev. 1989 Jan;47(1):23–5.

  96. Qu X, Tang Y, Hua S. Immunological approachestowards cancer and infl ammation: a crosstalk. Front Immunol. 2018 Mar 20;9:563. DOI:10.3389/fi mmu.2018.00563

  97. Schetter AJ, Heegaard NH, Harris CC. Infl ammationand cancer: interweaving microRNA, freeradical, cytokine and p53 pathways. Carcinogenesis.2010 Jan 1;31(1):37–49.

  98. Grivennikov SI, Greten FR, Karin M. Immunity,infl ammation, and cancer. Cell. 2010 Mar19;140(6):883–99.

  99. Munn L. Cancer and Infl ammation. Wiley InterdiscipRev Syst Biol Med. 2017 Mar;9(2). DOI:10.1002/wsbm.1370

  100. Aguilar-Cazares D, Chavez-Domínguez R, Carlos-Reyes A, López-Camarillo C, Hernández dela Cruz ON, López-González JS. Contributionof angiogenesis to inflammation and cancer.Front Oncol. 2019 Dec 12;9:1399. DOI: 10.3389/fonc.2019.01399

  101. Qian S, Golubnitschaja O, Zhan X. Chronicinfl ammation: key player and biomarker-set topredict and prevent cancer development andprogression based on individualized patient profiles. EPMA J. 2019 Nov 20;10(4):365–81.

  102. Jones D, Neal RD, Duffy SRG, Scott SE,Whitaker KL, Brain K. Comment. Impact of theCOVID-19 pandemic on the symptomatic diagnosisof cancer: the view from primary care. LancetOncol. 2020 Jun;21(6):748–50.

  103. Zhang L, Zhu F, Xie L, Wang C, Wang J, Chen R,et al. Clinical characteristics of COVID- 19-infectedcancer patients: a retrospective case study inthree hospitals within Wuhan, China. Ann Oncol.2020 Jul;31(7):894–901.

  104. Ghosh S, Das S, Mondal R, Abdullah S, SultanaS, Singh S, et al. A review on the effect ofCOVID-19 in type 2 asthma and its management.Int Immunopharmacol. 2021 Feb;91:107309.DOI: 10.1016/j.intimp.2020.107309

  105. Zhao Q, Meng M, Kumar R, Wu Y, Huang J, LianN, et al. The impact of COPD and smoking historyon the severity of COVID–19: a systemicreview and meta-analysis. J Med Virol. 2020Oct;92(10):1915–21.

  106. Liu S, Zhi Y, Ying S. COVID-19 and asthma:refl ection during the pandemic. Clin Rev AllergyImmunol. 2020 Aug;59(1):78–88.

  107. Leung JM, Yang CX, Tam A, Shaipanich T,Hackett TL, Singhera GK, et al. ACE-2 expressionin the small airway epithelia of smokersand COPD patients: implications for COVID-19.Eur Respir J. 2020 May 14;55(5):2000688.DOI: 10.1183/13993003.00688-2020

  108. Figueira Gonçalves JM, Golpe R, García-TalaveraI. Chronic obstructive pulmonary disease andSARS-CoV-2 infection. What do we know so far?Arch Bronconeumol. 2020 Jul;56 Suppl 2:5–6.English, Spanish.

  109. Kreutz R, El-Hady Algharably EA, Azizi M, DobrowolskiP, Guzik T, Januszewicz A, et al. Hypertension,the renin–angiotensin system, and therisk of lower respiratory tract infections and lunginjury: implications for COVID-19. CardiovascRes. 2020 Aug 1;116(10):1688–99.

  110. Global Strategy for Asthma Management andPrevention [Internet]. Wisconsin: Global Initiativefor Asthma; 2019 Jun [cited 2020 Dec 24].Chapter 1, Defi nition, description, and diagnosisof asthma; p. 16. Available at: https://ginasthma.org/wp-content/uploads/2019/06/GINA-2019-main-report-June-2019-wms.pdf

  111. Hosoki K, Chakraborty A, Sur S. Molecular mechanismsand epidemiology of COVID- 19 froman allergist’s perspective. J Allergy Clin Immunol.2020 Aug;146(2):285–99.

  112. Carrillo T, Martínez JA, Cumplido JA. IgE yasma: El resurgir de una vieja relación. Diferentestipos de respuesta infl amatoria en el asma.Arch Bronconeumol. 2006;42 Suppl 1:13–9. DOI:10.1157/13097252. Spanish.

  113. García-Pachón E, Zamora-Molina L, Soler-Sempere MJ, Baeza-Martínez C, Grau- DelgadoJ, Canto-Reig V, et al. Asthma prevalencein patients with SARS-CoV-2 infection detectedby RT-PCR not requiring hospitalization. RespirMed. 2020 Sep;171:106084. DOI: 10.1016/j.rmed.2020.106084

  114. Grandbastien M, Piotin A, Godet J, Abessolo-Amougou I, Ederlé C, Enache I, et al. SARS-CoV-2pneumonia in hospitalized asthmatic patients didnot induce severe exacerbation. J Allergy ClinImmunol Pract. 2020 Sep;8(8):2600–7.

  115. Chhiba KD, Patel GB, Vu THT, Chen MM, Guo A,Kudlaty E, et al. Prevalence and characterizationof asthma in hospitalized and nonhospitalizedpatients with COVID-19. J Allergy Clin Immunol.2020 Aug;146(2):307–14.e4.

  116. Skevaki C, Karsonova A, Karaulov A, XieM, Renz H. Asthma-associated risk forCOVID-19 development. J Allergy Clin Immunol.2020 Dec;146(6):1295–301.

  117. Abrams EM, ‘t Jong GW, Yang CL. Asthma andCOVID-19. CMAJ. 2020 May 19;192(20):E551.

  118. Carli G, Cecchi L, Stebbing J, Parronchi P, FarsiA. Is asthma protective against C COVID-19?Allergy. 2020 Jun 17;00:1–3. DOI: 10.1111/all.14426

  119. Holgate ST, Wenzel S, Postma DS, Weiss ST,Renz H, Sly PD. Asthma. Nat Rev Dis Primers.2015;1(1):15025. DOI:10.1038/nrdp.2015.25

  120. Mendes NF, Jara CP, Mansour E, Araújo EP, VellosoLA. Asthma and COVID-19: a systematicreview. Allergy Asthma Clin Immunol. 2021 Jan6;17(1):5.

  121. Calvielli AC, Notomi M, Wesley R. Branco ACCC,Sato MN, Alberca RW. The possible dual role ofthe ACE2 receptor in asthma and Coronavirus(SARS-CoV2) infection. Front Cell Infect Microbiol.2020 Sep 23;10:550571. DOI: 10.3389/fcimb.2020.550571

  122. Hughes-Visentin A, Mahesan Paul AB. Asthmaand COVID-19: what do we know now. ClinMed Insights Circ Respir Pulm Med. 2020 Oct23;14:1179548420966242.

  123. Öztürk AB, Çağlayan B. Angiotensin convertingenzyme-2 (ACE2) receptors, asthma and severeCOVID-19 infection risk. Eur Ann Allergy ClinImmunol. 2020 Nov;52(6):282–5.

  124. Morais-Almeida M, Pité H, Aguiar R, AnsoteguiI, Bousquet J. Asthma and the Coronavirus disease2019 pandemic: a literature review. Int ArchAllergy Immunol. 2020;181(9):680–8.




2020     |     www.medigraphic.com